Clinical trials: Pancreatic Disorders
Fibrosing Colonopathy
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of…
- Trial name
- NCT01652157
- Testing
- ULTRESA, PANCREAZE, CREON
- Where
- 123 sites in United States
- Volunteers
- 17 people
- Sponsor
- AbbVie
Pancreatic Cancer
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
This study is a multi center, open-label, dose escalation, Phase I/IIa study of EF-009 in up to 30 patients with borderline resectable and unresectable pancreatic cancer.
- Trial name
- NCT04381130
- Testing
- EF-009
- Volunteers
- 30 people
- Sponsor
- Everfront Biotech Co., Ltd.
Neoplasms
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
The primary objectives of the Phase I study 15404 are to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given once every 3 weeks in Japanese subjects with advanced, refractory solid tumors.
- Trial name
- NCT02485119
- Testing
- BAY94-9343
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
This study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy of ZB131 in patients with solid tumors where…
- Conditions
- Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic
- Trial name
- NCT05074472
- Testing
- ZB131
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- ZielBio, Inc.
Chronic Pancreatitis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult Participants
This study will test CBT-248, an experimental medicine being developed for chronic pancreatitis. Chronic pancreatitis causes ongoing inflammation and damage to the pancreas, which can cause pain and problems with digestion and…
- Trial name
- NCT07905053
- Testing
- CBT-248, Fasted - Period 1, Fed - Period 2
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cibus Therapeutics, Inc.
Cystic Fibrosis
A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
This is a Phase 2 open-label, dose-escalation study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with CF with at least one G542X allele.
- Trial name
- NCT04135495
- Testing
- ELX-02, Ivacaftor
- Where
- 10 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Eloxx Pharmaceuticals, Inc.
Advanced Solid Tumors
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors
- Trial name
- NCT06973564
- Testing
- JAB-23E73, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 344 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Metastatic Pancreatic Cancer
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
The purpose of this clinical research study is to learn if ixabepilone plus cetuximab improves survival when given as 1st line chemotherapy in subjects with metastatic pancreatic cancer compared to historical data.
- Trial name
- NCT00383149
- Testing
- Ixabepilone, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- R-Pharm
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal…
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
- Trial name
- ASPIRE (NCT05254171)
- Testing
- SBP-101, Nab-paclitaxel, Gemcitabine
- Where
- 93 sites in United States, Australia and 8 more
- Volunteers
- 600 people
- Sponsor
- Panbela Therapeutics, Inc.
Cystic Fibrosis
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis (CF).
- Trial name
- NCT03912233
- Testing
- VX-121, TEZ, VX-561
- Where
- 26 sites in United States, Germany and 3 more
- Volunteers
- 87 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pancreatic Neoplasms
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non…
- Trial name
- PAPRIKA (NCT00417209)
- Testing
- Larotaxel (XRP9881), 5-Fluorouracil, Capecitabine
- Where
- 21 sites in United States, Belgium and 19 more
- Volunteers
- 408 people
- Sponsor
- Sanofi
Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
The purpose of this study is to evaluate the long term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in CF participants 2 years of age and older.
- Trial name
- NCT05153317
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 71 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
A Study of Sweat Testing Using a Quantitative Patch
The primary aim of the study is to determine if the CF Quantum Sweat Test provides sweat chloride results that are equivalent to the results from traditional sweat testing.
- Trial name
- NCT01345617
- Where
- 3 sites in United States
- Volunteers
- 170 people
- Sponsor
- Polychrome Medical, Inc.
Pancreatic Cancer, Colorectal Cancer (CRC)
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has…
- Conditions
- Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
- Trial name
- NCT02955940
- Testing
- Ruxolitinib, Capecitabine, Regorafenib
- Where
- 9 sites in United States, Poland
- Volunteers
- 10 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumors
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer…
- Trial name
- EIK1004-001 (NCT06907043)
- Testing
- EIK1004-001 (IMP1707-001)
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 130 people
- Sponsor
- Eikon Therapeutics
Pancreatic Neoplasms
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel combined with gemcitabine in Chinese patients with metastatic pancreatic cancer.
- Trial name
- PANC-001 (NCT02017015)
- Testing
- nab-paclitaxel, Gemcitabine
- Where
- 15 sites in China
- Volunteers
- 83 people
- Sponsor
- Celgene
Carcinoma, Pancreatic Ductal
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
The purpose of the study is to evaluate a new treatment strategy for advanced pancreatic cancer disease by combining the new investigational medicinal product Atu027 with the standard chemotherapeutic gemcitabine.
- Trial name
- Atu027-I-02 (NCT01808638)
- Testing
- Atu027 & gemcitabine in lead in safety period, Atu027 & gemcitabine in treatment arm 1, Atu027 & gemcitabine in treatment arm 2
- Where
- 9 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Silence Therapeutics GmbH
Pancreatic Cancer, Pancratic Ductal Adenocarcinoma
A Study of GC203 TIL in PDCA (RJ)
This study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects, Tumor Infiltrating Lymphocytes
- Trial name
- NCT06828328
- Testing
- GC203 TIL
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Juncell Therapeutics
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Cystic Fibrosis
A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo
This study is designed to show how well tobramycin inhalation powder works and how safe it is when produced by a modified manufacturing process
- Trial name
- EDIT (NCT00918957)
- Testing
- Tobramycin Inhalation Powder
- Where
- 24 sites in Bulgaria, Egypt and 7 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.